You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 10/09/2015

Company Name Symbol %Change
Omnicell Makes a Move: Up 2.6%

Print Share

Dec 05, 2012 (Market movers via COMTEX) -- Up 2.6% to $15.74, Omnicell (NASDAQ:OMCL), is one of today's notable movers. The Dow is up 0.9% to 13,073 and the S&P is currently up 0.5% to 1,414.

In the past 52 weeks, Omnicell share prices have been bracketed by a low of $12.33 and a high of $18.15 and are now at $15.74, 28% above that low price. The 200-day and 50-day moving averages have moved 0.26% lower and 0.14% higher over the past week, respectively.

Potential upside of 12.2% exists for Omnicell, based on a current level of $15.74 and analysts' average consensus price target of $17.67. The stock should find initial support at its 200-day moving average (MA) of $14.46 and further support at its 50-day MA of $14.02.

Omnicell, Inc. provides an integrated suite of clinical infrastructure and workflow automation solutions for healthcare facilities. The Company's solutions include pharmacy and supply systems, clinical reference tools, an Internet-based procurement application, and decision support tools. Omnicell sells and leases its products and services to a range of healthcare facilities.


Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.